Summary
Abbott Laboratories (ABT) announced a significant strategic move by entering into a definitive agreement to acquire Exact Sciences Corporation for $105.00 per share in cash. This acquisition, structured as a merger where Exact Sciences will become a wholly-owned subsidiary of Abbott, represents a substantial investment by Abbott into the diagnostics and cancer screening market. The transaction is subject to customary closing conditions, including shareholder approval from Exact Sciences and regulatory clearance, such as the Hart-Scott-Rodino Antitrust Improvements Act. This deal is expected to bolster Abbott's presence in precision medicine and oncology. The financial implications include a commitment of up to $20 billion in bridge loans from Morgan Stanley Senior Funding, Inc. to finance the transaction. Abbott has scheduled an investor conference call to discuss the merger, indicating its strategic importance and the company's intent to provide detailed insights into the rationale and expected benefits of this acquisition.
Key Highlights
- 1Abbott Laboratories to acquire Exact Sciences Corporation for $105.00 per share in an all-cash transaction.
- 2The acquisition aims to significantly expand Abbott's footprint in the diagnostics and precision oncology sectors.
- 3Exact Sciences will become a wholly-owned subsidiary of Abbott upon completion of the merger.
- 4Transaction is subject to customary closing conditions, including Exact Sciences shareholder approval and antitrust regulatory review.
- 5Abbott has secured a commitment for up to $20 billion in bridge loans to finance the acquisition.
- 6The company will host an investor conference call on November 20, 2025, to discuss the merger.